Antitumor Agents: Development of Highly Potent Glycosidic Duocarmycin Analogues for Selective Cancer Therapy

Abstract

Better and better: The glycosidic prodrug (+)-1, which is based on duocarmycin antibiotics, was synthesized for selective cancer therapy. The drug was developed within the context of “antibody-directed enzyme prodrug therapy” (ADEPT). As a result of its outstanding QIC50 values, its excellent solubility, and easy synthesis it exceeds all other prodrugs produced to date. QIC50=comparative toxicity value between the prodrug and the drug.